CXCL17 and neoplasm: The results revealed that tumors with high CXCL17 expression had more active immune-related pathways, including IL6-JAK-STAT3 (Figure 7c), complement (Figure 7d), etc., but presented with less enrichment of some pathways proven to promote tumor development, such as E2F targets, G2M checkpoint, myc targets, wnt/beta-catenin, and so on (Figure 7e).